1921
Volume 103, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

The COVID-19 pandemic is showing an exponential growth, mandating an urgent need to develop an effective treatment. Indeed, to date, a well-established therapy is still lacking. We aimed to evaluate the safety and efficacy of hydroxychloroquine (HCQ) added to standard care in patients with COVID-19. This was a multicenter, randomized controlled trial conducted at three major university hospitals in Egypt. One hundred ninety-four patients with confirmed diagnosis of COVID-19 were included in the study after signing informed consent. They were equally randomized into two arms: 97 patients administrated HCQ plus standard care (HCQ group) and 97 patients administered only standard care as a control arm (control group). The primary endpoints were recovery within 28 days, need for mechanical ventilation, or death. The two groups were matched for age and gender. There was no significant difference between them regarding any of the baseline characteristics or laboratory parameters. Four patients (4.1%) in the HCQ group and 5 (5.2%) patients in the control group needed mechanical ventilation ( = 0.75). The overall mortality did not differ between the two groups, as six patients (6.2%) died in the HCQ group and 5 (5.2%) died in the control group ( = 0.77). Univariate logistic regression analysis showed that HCQ treatment was not significantly associated with decreased mortality in COVID-19 patients. So, adding HCQ to standard care did not add significant benefit, did not decrease the need for ventilation, and did not reduce mortality rates in COVID-19 patients.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.20-0873
2020-08-14
2021-01-16
Loading full text...

Full text loading...

/deliver/fulltext/14761645/103/4/tpmd200873.html?itemId=/content/journals/10.4269/ajtmh.20-0873&mimeType=html&fmt=ahah

References

  1. Zhu N et al., China Novel Coronavirus Investigating and Research Team, 2020. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382: 727733.
    [Google Scholar]
  2. Yin Y, Wunderink RG, 2018. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 23: 130137.
    [Google Scholar]
  3. Zhou P et al., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579: 270273.
    [Google Scholar]
  4. Bhatnagar T, Murhekar MV, Soneja M, Gupta N, Giri S, Wig N, Gangakhedkar R, 2020. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: protocol for restricted public health emergency use. Indian J Med Res 151: 184189.
    [Google Scholar]
  5. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, Choe KW, Kang YM, Lee B, Park SJ, 2020. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 35: e79.
    [Google Scholar]
  6. Cao B, 2020. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 382: 17871799.
    [Google Scholar]
  7. Gautret P et al., 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56: 105949.
    [Google Scholar]
  8. Molina JM, Delaugerre C, Goff JL, Mela-Lima B, Ponscarme D, Goldwirt L, de Castro N, 2020. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 50: 384.
    [Google Scholar]
  9. Gnegel G, Hauk C, Neci R, Mutombo G, Nyaah F, Wistuba D, Häfele-Abah C, Heide L, 2020. Identification of falsified chloroquine tablets in Africa at the time of the COVID-19 pandemic. Am J Trop Med Hyg 103: 7376.
    [Google Scholar]
  10. Xie M, Chen Q, 2020. Insight into 2019 novel coronavirus - an updated interim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis 94: 119124.
    [Google Scholar]
  11. Abena PM et al., 2020. Chloroquine and hydroxychloroquine for the prevention or treatment of COVID-19 in Africa: caution for inappropriate off-label use in healthcare settings. Am J Trop Med Hyg 102: 11841188.
    [Google Scholar]
  12. Skipper CP et al., 2020. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Intern Med M20M4207.
    [Google Scholar]
  13. Cavalcanti AB et al., Coalition COVID-19 Brazil I Investigators, 2020. Hydroxychloroquine with or without azithromycin in mild-to-moderate COVID-19. N Engl J Med. Available at: https://doi.org/10.1056/NEJMoa2019014.
    [Google Scholar]
  14. World Health Organization, 2020. Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease Is Suspected Interim Guidance. Available at: https://apps.who.int/iris/bitstream/handle/10665/331446/WHO-2019-nCoV-clinical-2020.4-eng.pdf?sequence=1&isAllowed=y. Accessed March 13, 2020.
    [Google Scholar]
  15. Egyptian Ministry of Health and Population (MOH), 2020. Diagnosis and Treatment Protocol for COVID-19. Available at: http://www.mohp.gov.eg/QuickServiceDetails.aspx?subject_id=3686. Accessed March 24, 2020.
    [Google Scholar]
  16. Faul F, Erdfelder E, Lang AG, Buncher A, 2007. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175191.
    [Google Scholar]
  17. Principi N, Esposito S, 2020. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect Dis. doi: 10.1016/S1473-3099(20)30296-6.
    [Google Scholar]
  18. Udwadia ZF, Malu KN, Rana D, Joshi SR, 2020. Hydroxychloroquine for COVID-19: what is our current state of knowledge? J Assoc Physicians India 68: 4852.
    [Google Scholar]
  19. Bhandari S et al., 2020. Characteristics, treatment outcomes and role of hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur city: an epidemio-clinical study. J Assoc Physicians India 68: 1319.
    [Google Scholar]
  20. Geleris J et al., 2020. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med 382: 24112418.
    [Google Scholar]
  21. Alexander PE, Debono VB, Mammen MJ, Iorio A, Aryal K, Deng D, Brocard E, Alhazzani W, 2020. COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. J Clin Epidemiol 123: 120126.
    [Google Scholar]
  22. Tang W et al., 2020. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 369: m1849.
    [Google Scholar]
  23. Sarma P et al., 2020. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review and meta-analysis. J Med Virol 92: 776785.
    [Google Scholar]
  24. Horby P et al., 2020. Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial. medRxiv. Available at: https://doi.org/10.1101/2020.07.15.20151852.
    [Google Scholar]
  25. Boulware DR et al., 2020. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med 383: 517525.
    [Google Scholar]
  26. Khan MS, Butler J, 2020. Hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med 383. Available at: https://doi.org/10.1056/NEJMc2023617.
    [Google Scholar]
  27. Mohamed AA, Mohamed N, Mohamoud S, Zahran FE, Khattab RA, El-Damasy DA, Alsayed E, Abd-Elsalam S, 2020. SARS-CoV-2: the path of prevention and control. Infect Disord Drug Targets. Available at: https://doi.org/10.2174/1871526520666200520112848.
    [Google Scholar]
  28. Sarin SK et al., APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study, 2020. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int 111.
    [Google Scholar]
  29. Abd-Elsalam S, Elkadeem M, Glal KA, 2020. Chloroquine as chemoprophylaxis for COVID-19: will this work? Infect Disord Drug Targets. Available at: https://doi.org/10.2174/1871526520666200726224802.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.20-0873
Loading
/content/journals/10.4269/ajtmh.20-0873
Loading

Data & Media loading...

  • Received : 17 Jul 2020
  • Accepted : 07 Aug 2020
  • Published online : 14 Aug 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error